2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.35 Schneider

PP01.35 Schneider - Abstract

Pdf Summary

Repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor, shows promising results in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) based on the TRIDENT-1 trial. The study reports durable efficacy and manageable safety up to 14 months. In the TKI-naïve cohort, the confirmed objective response rate (cORR) was 79%, with a median duration of response (DOR) and progression-free survival (PFS) of 34.1 and 35.7 months, respectively. In the subgroup with prior TKI treatment and no chemotherapy, cORR was 38%, with a median DOR of 14.8 months and PFS of 9.0 months. Patients with the ROS1 G2032R mutation had a cORR of 59%. The most common treatment-emergent adverse event was dizziness, managed through interventions and prophylactic measures. Intracranial activity was also observed. Overall, repotrectinib demonstrated consistent efficacy and safety outcomes. The study offers insight into the potential of repotrectinib in treating ROS1 NSCLC, highlighting its durable efficacy and manageable safety profile, particularly in patients with different treatment histories.

Keywords

Repotrectinib

ROS1 tyrosine kinase inhibitor

non-small cell lung cancer

TRIDENT-1 trial

objective response rate

progression-free survival

ROS1 G2032R mutation

treatment-emergent adverse event

Intracranial activity

durable efficacy